Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Flow Technologies in Bioscience Review

Published: Monday, October 29, 2012
Last Updated: Monday, October 29, 2012
Bookmark and Share
The conference highlighted the importance of collaboration between chemists, biologists, material scientists, IT and mechanical engineers, and of course equipment vendors to increase the effectiveness of flow technologies within Bioscience.

Microsaic Systems presented at ‘Flow Technologies in Bioscience’ organised by Labstract and held at the newly opened Stevenage Bioscience Catalyst Innovation centre.

Suki Klair, CEO at Labstract organised a stimulating agenda of speakers with a focus on enabling new applications via flow technologies.

Steve Jordan, Head of R&D, Biotage chaired the event and set the scene by commenting that continuous processing was gaining ground within the pharma industry and welcomed the speakers who ranged from academic thought leaders in flow, including Professor Steve Haswell, University of Hull, to equipment vendors including Microsaic Systems.

Many people are still on the fence about the benefits of flow chemistry, and in some cases it doesn’t make sense to change processes that are working in batch. However, as chemists search for more novel transformations they are forced to look at hazardous transformations such as ozonolysis and diazotisation and this is where flow chemistry can provide significant safety improvements to batch methods. Flow technology is here to stay. It will not replace batch chemistry but it does provide another tool in the chemist’s tool box.

Syrris highlighted a compelling example of this from the BOSS group in Rio de Janeiro where flow through a biocatalyst had increased catalyst efficiency by 10 times, compared to batch. They also mentioned a new electrochemistry module that will be available next year. Electrochemistry is a lost art so a database of reactions will be built up by key users and shared by Syrris on their website.

Matt O’Brien, Keele University talked about his time in the Ley lab, University of Cambridge where gas-liquid reactions have been successfully performed safely in flow with hazardous gases such as ozone using the innovative tube-in-a-tube reactors available from Uniqsis and Cambridge Reactor Design.

Bryan McCullough, Microsaic showed the first example of mass spectrometry being used to monitor a flow reaction which was jointly published with the Ley group, University of Cambridge. Mass spectrometry is not new, but the new miniature MS, the MiD fits in a fumehood, giving chemists access to this useful technique. Both Mettler Toledo, manufacturer of the Flow-IR and Microsaic showed that using on-line monitoring can greatly increase reaction understanding. The Ley group uses these technologies to increase the speed of reaction optimisation and identify new reaction intermediates and pathways.

Chris Selway gave us an insight into what is happening at Cyclofluidic. Their novel synthesis platform allows compounds to be synthesised from a set of pre-loaded monomers, purified, analysed, and then injected into a biological assay. Their algorithm “learns” which compounds are most potent and the computer decides which compound to make next. Each cycle takes 1 hour and over a weekend a candidate compound can be found. This is “closing the loop” of drug discovery, enabled by flow technologies.

Professor Steve Haswell, University of Hull is at the cutting edge of lab-on-a-chip technologies and highlighted the potential use of functionalised microfluidic devices that could be used by police and doctors for point-of-use applications. It was interesting to hear that regulatory bodies are positive about these new, disruptive technologies and actually the barrier-to-entry is the institutions who will resist change, in spite of cost and time savings.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos